Implantable Cardiac Rhythm Management Device Market Report 2026

Implantable Cardiac Rhythm Management Device Market Overview

• Implantable Cardiac Rhythm Management Device market size has reached to $17.7 billion in 2025 • Expected to grow to $24.91 billion in 2030 at a compound annual growth rate (CAGR) of 7.2% • Growth Driver: The Rising Prevalence of Cardiac Disorders Fueling the Growth of the Implantable Cardiac Rhythm Management Device Market • Market Trend: Implantable Cardiac Defibrillators To Reshape The Implantable Cardiac Rhythm Management Devices Market • North America was the largest region in 2025.

What Is Covered Under Implantable Cardiac Rhythm Management Device Market?

Implantable cardiac rhythm management devices refer to small battery-operated devices that are inserted inside the body and connected to the heart. It is used to maintain and manage heart rhythm. The main devices implantable cardiac rhythm management devices are cardiac resynchronization therapy, defibrillators, and pacemakers. Cardiac resynchronization therapy (CRT) refers to a particular type of treatment for severe cardiac rhythm issues. The various applications involved are bradycardia, tachycardia, and others which are used in hospitals, specialty cardiac centers, and others.

What Is The Implantable Cardiac Rhythm Management Device Market Growth Forecast?

The implantable cardiac rhythm management device market size is expected to see strong growth in the next few years. It will grow to $24.91 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing adoption of smart implantable devices, rising focus on remote patient monitoring, expansion of AI-enabled rhythm analysis, growing demand for minimally invasive cardiac procedures, increasing healthcare investments in cardiac care infrastructure. Major trends in the forecast period include increasing adoption of remote cardiac monitoring capabilities, rising use of advanced battery technologies, growing integration of wireless cardiac devices, expansion of minimally invasive implantation techniques, enhanced focus on device longevity and reliability.

Global Implantable Cardiac Rhythm Management Device Market Segmentation

1) By Device: Cardiac Resynchronization Therapy, Defibrillators, Pacemakers 2) By Application: Bradycardia, Tachycardia, Other Applications 3) By End-Use: Hospitals, Specialty Cardiac Centers, Other End-Uses Subsegments: 1) By Cardiac Resynchronization Therapy (CRT): CRT-P (Pacemaker), CRT-D (Defibrillator) 2) By Defibrillators: Implantable Cardioverter Defibrillators (ICDs), Subcutaneous Implantable Defibrillators (S-ICDs) 3) By Pacemakers: Single-Chamber Pacemakers, Dual-Chamber Pacemakers, Biventricular Pacemakers

What Are The Drivers Of The Implantable Cardiac Rhythm Management Device Market?

The increasing prevalence of cardiac disorders is expected to boost the growth of the implantable cardiac rhythm management devices market going forward. Cardiac disorder refers to a type of condition that affects the heart or blood vessels. Implantable cardiac rhythm management devices are used to help patients with heart failure and reduced left ventricular function to improve systolic function by resynchronizing the heart contraction and restoring normal heart rhythm in the event of life-threatening rapid ventricular arrhythmias. Hence, the increasing prevalence of cardiac disorders will boost the demand for implantable cardiac rhythm management devices. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the increasing prevalence of cardiac disorders is driving the growth of the implantable cardiac rhythm management device industry. The rising aging population is expected to propel the growth of the implantable cardiac rhythm management devices market going forward. An aging population refers to a situation where a large proportion of a country's citizens are getting older, and there is a higher average age of the people in that population. Implantable cardiac rhythm management devices are commonly used in the aging population to address and manage various heart-related conditions. For instance, in January 2024, according to the Population Reference Bureau, a US-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050, a 47% increase. This age group’s share of the overall population is also projected to rise from 17% to 23% during the same period. Therefore, the rising aging population is driving the growth of the implantable cardiac rhythm management devices industry.

Key Players In The Global Implantable Cardiac Rhythm Management Device Market

Major companies operating in the implantable cardiac rhythm management device market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Japan Lifeline Co Ltd, Lepu Medical Technology Beijing Co Ltd, Shree Pacetronix Ltd, Osypka Medical GmbH, Sorin Group Italia Srl, Medico SpA, Vitatron Holding BV, Pacetronix Ltd, CardioElectronica SA, Imricor Medical Systems Inc, Impulse Dynamics plc, Kardium Inc, Cortrium ApS, EBR Systems Inc

Global Implantable Cardiac Rhythm Management Device Market Trends and Insights

Major companies operating in the implantable cardiac rhythm management devices market focus on the launch of innovative products such as implantable cardiac defibrillators. Implantable cardiac defibrillators are a small, battery-powered device implanted under the skin, typically near the collarbone. For instance, in October 2023, MicroPort CRM, a France-based implantable cardiac defibrillator manufacturer announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICDs) and INVICTA defibrillation implantable devices. The ULYS ICD integrates cutting-edge technology with minimal energy consumption, leading to the most extended anticipated lifespan. It also features AutoMRI function and PARAD arrhythmia discrimination algorithm that helps to automatically switch the device. The INVICTA defibrillation leads to consistently sensing electrical signals from the right ventricle of the heart, providing pacing therapy if the heart rate is too low.

Regional Outlook

North America was the largest region in the implantable cardiac rhythm management device market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain

What Defines the Implantable Cardiac Rhythm Management Device Market?

The implantable cardiac rhythm management devices market consists of sales of the leadless pacemaker, insertable cardiac monitor, cardiac leads, and subcutaneous implantable defibrillator (S-ICD). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.